AbbVie | ABBV

Stock Price
167.88
Daily Change
-2.59 -1.52%
Monthly
4.09%
Yearly
21.89%
Q2 Forecast
168.49
Peers Price Chg Day Year Date
Eisai 6,594.00 -55.00 -0.83% -37.53% Jun/12
AbbVie 167.88 -2.59 -1.52% 21.89% Jun/11
Abbott 105.86 -1.76 -1.64% 4.40% Jun/11
ALKERMES 24.77 0.58 2.38% -20.68% Jun/11
Amgen 300.69 -3.84 -1.26% 38.34% Jun/11
AstraZeneca 12,376.00 -224.00 -1.78% 4.62% Jun/11
Biogen 225.68 -0.42 -0.19% -27.99% Jun/11
BioMarin Pharmaceutical 83.87 0.93 1.12% -10.13% Jun/11
Bristol-Myers Squibb 43.01 0.44 1.03% -33.59% Jun/11
Gilead Sciences 64.89 -0.35 -0.54% -16.66% Jun/11
GlaxoSmithKline 1,615.00 -6.00 -0.37% 17.56% Jun/11
J&J 146.67 -0.38 -0.26% -8.27% Jun/11
Eli Lilly 867.00 -0.73 -0.08% 94.70% Jun/11
Medtronic 81.95 -1.28 -1.54% -2.76% Jun/11
Merck 131.87 0.54 0.41% 20.03% Jun/11
Neurocrine Biosciences 133.15 -1.55 -1.15% 42.42% Jun/11
Novartis 93.98 -0.32 -0.34% 3.46% Jun/11
Pacira 28.97 0.14 0.49% -19.80% Jun/11
Pfizer 28.04 -0.14 -0.50% -29.72% Jun/11
Perrigo 28.21 1.00 3.66% -14.53% Jun/11
Ultragenyx Pharmaceutical 41.40 -0.57 -1.36% -19.46% Jun/11
Regeneron Pharmaceuticals 1,010.54 9.09 0.91% 34.02% Jun/11
Roche Holding 241.60 1.90 0.79% -13.73% Jun/11
Sanofi 89.89 -0.38 -0.42% -5.40% Jun/11
UCB 131.40 1.35 1.04% 54.62% Jun/11
United Therapeutics 275.76 0.51 0.19% 21.00% Jun/11
Vertex Pharmaceuticals 481.53 -1.51 -0.31% 41.38% Jun/11
Zoetis 178.69 -0.31 -0.17% 7.94% Jun/11

Indexes Price Day Year Date
US500 5384 14.53 0.27% 23.23% Jun/12

AbbVie traded at $167.88 this Tuesday June 11th, decreasing $2.59 or 1.52 percent since the previous trading session. Looking back, over the last four weeks, AbbVie lost 4.09 percent. Over the last 12 months, its price rose by 21.89 percent. Looking ahead, we forecast AbbVie to be priced at 168.49 by the end of this quarter and at 165.42 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.